ZELLUNA ZLNA ADDITIONAL REGULATED INFORMATION REQUIRED TO BE DISCLOSED UNDER THE LAWS OF A MEMBER STATE

Zelluna ASA - Extraordinary General Meeting held on November 25, 2025

25. November 2025 kl. 11:32
Original kilde

Oslo, November 25, 2025: Zelluna ASA held its extraordinary general meeting today November 25, 2025. All the matters on the agenda were approved.

The minutes from the meeting are enclosed and available at the company's website.

For further information, please see www.zelluna.com (http://www.zelluna.com) or contact:

Anders Tuv, Chairman of the Board of Directors of Zelluna ASA Email: at@radforsk.no (https://www.globenewswire.com/Tracker?data=ooZhdsLPYBvlQfnzSn4SZEfK73BmQ9uPLpbJ seqk1D-laRWCY3-DpxxjVU4Mb4y2R9-Xu_6eT20VQHyCGC7xwA==) Phone: +47 982 06 826

Namir Hassan, CEO, Zelluna ASA Email: namir.hassan@zelluna.com (https://www.globenewswire.com/Tracker?data=gAX3Ok8-kobzfd8Pg_Pxah_sGLsD9c1SgSg- T4j3NS8zP1j2n9M3u186ZzZcWaqo3TuSEsjJVW6D_XU_sYvCMRFsOVZMzb8lumbjfwmrSP_GMZ7ZQ2fH h296RZEWJsR7) Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA Email: hans.eid@zelluna.com (https://www.globenewswire.com/Tracker?data=rjuXpQu3XeEUQp9jisPlHAHLaEhk16dazF16 gHhecH4jglusnh4FNg1afbtRLLKzHaJSqw5F5Nv2nJJIRBnKCpz39Raw162uF4aBLkh2wJ5L4xzyns68 UZU_eDAu2O62) Phone: +47 482 48632

Vedlegg

PDF
Minutes of the Extraordinary General Meeting in Zelluna ASA.pdf
PDF
Appendices to the EGM.pdf

Andre nyheter

15.01.2026

Zelluna ASA: Approval and publication of prospectus

Les mer →
17.12.2025

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World's First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours

Les mer →
17.12.2025

Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk studie i Storbritannia for første studie på mennesker av ZI-MA4-1 (ZIMA-101), verdens første MAGE-A4-rettede TCR-NK celleterapi for solide kreftformer.

Les mer →